Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13

被引：0

作者：

Park, Won ^{[1
]}

Miranda, Pedro ^{[2
,3
]}

Brzosko, Marek ^{[4
]}

Wiland, Piotr ^{[5
]}

Gutierrez-Urena, Sergio ^{[6
]}

Mikazane, Helena ^{[7
]}

Lee, Yeon-Ah ^{[8
]}

Smiyan, Svitlana ^{[9
]}

Lim, Mie-Jin ^{[1
]}

Kadinov, Vladimir ^{[10
]}

Abud-Mendoza, Carlos ^{[11
,12
]}

Son, YoungKi ^{[13
]}

Yoo, Dae-Hyun ^{[14
]}

Braun, Juergen ^{[15
]}

机构：

[1] Inha Univ Hosp, Inchon, South Korea

[2] Univ Chile, Santiago, Chile

[3] Ctr Estudios Reumatol, Santiago, Chile

[4] Pomeranian Med Univ, Dept Rheumatol & Internal Dis, Szczecin, Poland

[5] Med Univ Wroclaw, Wroclaw, Poland

[6] Antiguo Hosp Civil Guadalajara, Guadalajara, Jalisco, Mexico

[7] Outpatient Clin ORTO, Riga, Latvia

[8] Kyung Hee Univ, Seoul, South Korea

[9] Ternopil Univ Hosp, Municipal Inst Ternopil Reg Council, Ternopol, Ukraine

[10] Multiprofile Hosp Act Treatment Sv Marina, Varna, Bulgaria

[11] Univ Autonoma San Luis Potosi, Hosp Cent, San Luis Potosi, Mexico

[12] Univ Autonoma San Luis Potosi, Fac Med, San Luis Potosi, Mexico

[13] CELLTRION, Inchon, South Korea

[14] Hanyang Univ, Hosp Rheumat Dis, Seoul 133791, South Korea

[15] Rheumazentrum Ruhrgebiet, Herne, Germany

来源：

ARTHRITIS AND RHEUMATISM | 2013年 / 65卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

L15

引用

页码：3326 / 3326

页数：1

共 50 条

[21] Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar(CT-P13) in patients with inflammatory bowel disease
María Fernanda Guerra Veloz
Federico Argüelles-Arias
Luisa Castro Laria
Belén Maldonado Pérez
Antonio Benítez Roldan
Raúl Perea Amarillo
Vicente Merino Bohórquez
Miguel Angel Calleja
ángel Caunedo álvarez
ángel Vilches Arenas
World Journal of Gastroenterology, 2018, (46) : 5288 - 5296
[22] Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
Guerra Veloz, Maria Fernanda
Arguelles-Arias, Federico
Castro Laria, Luisa
Maldonado Perez, Belen
Benitez Roldan, Antonio
Perea Amarillo, Raul
Merino Bohorquez, Vicente
Angel Calleja, Miguel
Caunedo Alvarez, Angel
Vilches Arenas, Angel
WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (46) : 5288 - 5296
[23] CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease
Albshesh, Ahmad
Ben-Horin, Shomron
EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (10) : 971 - 978
[24] A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease
Farkas, Klaudia
Molnar, Tamas
IMMUNOTHERAPY, 2018, 10 (02) : 107 - 117
[25] Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health
Braun, Juergen
Kudrin, Alex
BIOLOGICALS, 2016, 44 (04) : 257 - 266
[26] Comparative effectiveness of the biosimilar CT-P13
Yoo, Dae Hyun
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2017, 6 (08) : 693 - 712
[27] Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases
Sieczkowska, Joanna
Jarzebicka, Dorota
Meglicka, Monika
Oracz, Grzegorz
Kierkus, Jaroslaw
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (05) : 729 - 735
[28] ANKYLOSING SPONDYLITIS COEXISTING WITH BEHCET'S DISEASE: SUCCESSFUL TREATMENT WITH CT-P13 INFLIXIMAB
Athanassiou, P.
Kostopoulos, M.
Spyridis, A.
Katsavouni, C.
Tzanavari, A.
Pantelidis, D.
OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S504 - S504
[29] A RETROSPECTIVE ANALYSIS OF LONG TERM SAFETY UP TO FIVE YEARS OF INFLIXIMAB BIOSIMILAR CT-P13 IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS
Kim, Tae-Hwan
Lee, Shin-Seok
Park, Won
Song, Yeong Wook
Suh, Chang-Hee
Kim, Sookyoung
Lee, Youngnam
Yoo, DaeHyun
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1159 - 1160
[30] Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases
Hannah A. Blair
Emma D. Deeks
BioDrugs, 2016, 30 : 469 - 480

← 1 2 3 4 5 →